Valuable Targets

Deciphering VEGF Inhibitors and Keeping Up with Their Recent Developments

27 December 2023
3 min read

VEGF, or vascular endothelial growth factor, plays a crucial role in the human body by promoting the growth of new blood vessels, a process known as angiogenesis. It is a protein that stimulates the formation of blood vessels during embryonic development and wound healing. In adults, VEGF helps maintain the integrity of existing blood vessels and supports the growth of new vessels in response to tissue damage or low oxygen levels. However, abnormal VEGF expression can lead to various diseases, including cancer and age-related macular degeneration. Understanding the role of VEGF is essential for developing therapies that target angiogenesis and regulate blood vessel growth in different pathological conditions.

The analysis of the target VEGF reveals a competitive landscape with several companies showing significant growth and R&D progress. Roche Holding AG, Novartis AG, and SAMSUNG BIOLOGICS Co., Ltd. are among the companies with the highest number of drugs in advanced stages of development. The approved indications for VEGF-targeted therapies cover a wide range of cancers and ophthalmic conditions, indicating the potential of these therapies in treating various diseases. Monoclonal antibodies and biosimilars are the most rapidly progressing drug types, suggesting intense competition in the market. China, the European Union, and the United States are leading in terms of drug development under the target VEGF. The future development of VEGF-targeted therapies is expected to be driven by continuous R&D efforts and global collaborations.

How do they work?

VEGF inhibitors are a type of medication that work by blocking the activity of vascular endothelial growth factor (VEGF). VEGF is a protein that plays a crucial role in the formation of new blood vessels, a process known as angiogenesis. In the context of biomedicine, VEGF inhibitors are primarily used in the treatment of various diseases characterized by excessive blood vessel growth, such as certain types of cancers and age-related macular degeneration.

By inhibiting VEGF, these medications can help prevent the growth and spread of tumors by reducing the blood supply that fuels their growth. In the case of age-related macular degeneration, VEGF inhibitors can slow down the abnormal growth of blood vessels in the retina, which can lead to vision loss.

VEGF inhibitors can be administered through different routes, including intravenous infusion or injection, and some are available in oral form. Common examples of VEGF inhibitors include bevacizumab, ranibizumab, and aflibercept. It's important to note that VEGF inhibitors may have potential side effects, such as high blood pressure, bleeding, and impaired wound healing, which should be carefully monitored during treatment.

List of VEGF Inhibitors

The currently marketed VEGF inhibitors include:

For more information, please click on the image below.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

What are VEGF inhibitors used for?

VEGF inhibitors are used in the treatment of various diseases characterized by excessive blood vessel growth, such as certain types of cancers and age-related macular degeneration. For more information, please click on the image below to log in and search.

图表

低可信度描述已自动生成

How to obtain the latest development progress of VEGF inhibitors?

In the Synapse database, you can keep abreast of the latest research and development advances of VEGF inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 表格

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

TQB2450: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ESMO_ASIA
ESMO 2023
4 min read
TQB2450: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ESMO_ASIA
27 December 2023
On 2 Dec 2023, the latest clinical trial about TQB2450 for the treatment for patients with hepatocellular carcinoma at high risk of recurrence was presented in 2023 ESMO_ASIA.
Read →
LEO Pharma Inc. has confirmed that the FDA has endorsed Adbry® (tralokinumab-ldrm) to manage adolescents aged 12-17 with moderate to severe eczema
Latest Hotspot
3 min read
LEO Pharma Inc. has confirmed that the FDA has endorsed Adbry® (tralokinumab-ldrm) to manage adolescents aged 12-17 with moderate to severe eczema
27 December 2023
LEO Pharma Inc. has disclosed that the FDA has recently broadened the sanctioned use of Adbry (tralokinumab-ldrm) by authorizing its application for young individuals.
Read →
What is the significance of liposomal drug delivery systems?
Knowledge Base
3 min read
What is the significance of liposomal drug delivery systems?
27 December 2023
Liposomal drug delivery systems are unique formulations that have gained significant attention in recent years due to their ability to enhance the pharmacokinetics and targeting of certain medications.
Read →
Understanding TNF Inhibitors and Methods to Keep Abreast of Their Recent Developments
Understanding TNF Inhibitors and Methods to Keep Abreast of Their Recent Developments
27 December 2023
The development of TNF inhibitors has been a significant advancement in the treatment of autoimmune diseases.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.